Golden Sun Health Technology Group Limited reported that on August 27, 2025 it received formal notice from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the minimum stockholders’ equity requirement for listing on The Nasdaq Capital Market. The company now meets all applicable criteria for continued listing, although Nasdaq will continue to monitor its status and could initiate a new delisting process if future periodic financial statements show that it no longer satisfies the minimum stockholders’ equity rule.
Golden Sun Health Technology Group Limited reports that its two accredited investors have fully exercised their warrant and converted all principal and interest under a prior convertible note into equity. On August 22, 2025, this transaction resulted in the issuance of 6,747,926 Class A ordinary shares to the investors. The original note had an aggregate principal amount of $5,000,000.
The company states that the carrying value of the note and warrant, about $9.4 million as of March 31, 2025, will be reclassified to total equity as of August 25, 2025. Because this increases shareholders’ equity, the company believes it now meets Nasdaq’s minimum $2.5 million shareholder equity requirement for continued listing and is waiting for a formal compliance determination from Nasdaq staff.
Form 144 notice by an insider of Golden Sun Health Technology Group Limited (GSUN) reporting a proposed sale of Class A ordinary shares. The filing lists a proposed sale of 140,108 Class A ordinary shares through WestBull Securities Limited (Hong Kong) on the Nasdaq with an aggregate market value of $378,291.60 and 1,577,944 shares outstanding reported. The table discloses prior acquisitions of Class A shares: 14,460 shares purchased 04/02/2020, 57,840 shares purchased 10/19/2020, and 4,820 shares purchased 10/19/2020, with payment in USD. The filer attests they possess no undisclosed material adverse information and includes the standard Rule 144 and signature attestations.
Golden Sun Health Technology Group Limited is notifying investors about upcoming shareholder meetings and related proxy materials. The company will hold an extraordinary general meeting for holders of Class A ordinary shares on September 25, 2025, followed by its 2025 annual general meeting of shareholders on the same date.
The company is distributing a combined notice and proxy statement for Class A shareholders and a separate notice and proxy statement for Class B shareholders, both dated August 15, 2025. It is also providing proxy cards for Class A and Class B holders so they can vote on the matters to be presented at these meetings.
Golden Sun Health Technology Group Limited filed an amended Form 6-K to add details about an amendment to its existing financing. The company had previously issued a Senior Secured Convertible Note with an aggregate principal amount of $5,000,000 to two accredited investors under a Securities Purchase Agreement dated October 28, 2024, with closing on December 3, 2024. On August 15, 2025, the company and these investors signed Amendment No. 1 to the note, which removes the Adjusted Floor Price defined in the original note and any related adjustments. The amendment is attached as Exhibit 4.1 and this amended Form 6-K is also incorporated by reference into the company’s effective Form F-1 registration statement and related prospectuses.
Golden Sun Health Technology Group Limited furnished a Form 6-K that is incorporated by reference into its effective Form F-1 registration statement. The filing states that Unaudited Condensed Consolidated Financial Statements as of March 31, 2025 and for the six months ended March 31, 2025 and 2024 are attached as Exhibit 99.1, and that an Operating and Financial Review and Prospects for the same periods is attached as Exhibit 99.2.
The report contains a detailed cautionary statement about forward-looking statements and lists key risk assumptions including financial projections, growth and expansion execution, economic and political conditions, capital requirements, talent retention, competition in the education industry, and other assumptions. The document is signed on the company’s behalf by its Chief Executive Officer.